EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee iD, Soo Jung Choi, Sang Min Park iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71261 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Sangwoo Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Seoul National University Graduate School, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Metformin. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gachon University Gil Medical Center, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin. Materials and Methods We conducted a nationwide active‐comparator new‐user cohort study with a 90‐day adherent‐survivor landmark design, using the Korean National Health Insurance Service database linked with national health check‐up and mortality data (2014–2022). Adults with newly diagnosed Type 2 diabetes receiving metformin who newly initiated SGLT2 inhibitors or DPP‐4 inhibitors as add‐on therapy were identified. This study was designed as a 90‐day adherent‐survivor landmark analysis. Propensity score matching was performed in a 1:1 ratio, yielding 10 013 matched pairs. The primary outcome was incident depression, defined as ≥ 2 outpatient or inpatient claims with ICD‐10 codes F32–F33. The secondary outcome was suicide mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs) under intention‐to‐treat and as‐treated approaches.

Results

Among 38 297 eligible participants, 300 depression events occurred among SGLT2 inhibitor users and 391 among DPP‐4 inhibitor users in the matched cohort. Initiation of SGLT2 inhibitors was associated with a lower risk of depression compared with DPP‐4 inhibitors (HR 0.85, 95% CI 0.73–0.99). Similar findings were observed in as‐treated analyses (HR 0.80, 95% CI 0.65–0.98). Associations were generally consistent across clinically relevant subgroups and appeared more pronounced among older adults, females and individuals with greater comorbidity burden. Suicide mortality was infrequent in both groups.

Conclusions

Among 90‐day adherent survivors with Type 2 diabetes receiving metformin, initiation of SGLT2 inhibitors as add‐on therapy was associated with a lower risk of incident depression compared with DPP‐4 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2MetforminDepressionHypoglycemic AgentsHumansFemaleMiddle AgedMaleAgedRepublic of KoreaIncidenceAdultCohort StudiesDrug Therapy, Combination

Stichwörter der Autor:innen

DPP‐IV inhibitorSGLT2 inhibitorantidiabetic drugcohort studyobservational studypharmaco‐epidemiology

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsMetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Seoul National University Graduate School, Seoul National University, Seoul, Republic of Korea.
  • Department of Biomedical Informatics, Korea University College of Medicine, Seoul, South Korea.
  • Department of Medicine, CHA University School of Medicine, Pocheon, Korea.
  • Department of Internal Medicine, (Medical Corporation) Namchon Medical Foundation, Shihwa Medical Center, Siheung-si, Gyeonggi-do, Korea.
  • Department of Family Medicine, Gachon University Gil Medical Center, Incheon, South Korea.
  • Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

ORCID-Profile: Dae Ho Lee, Sang Min Park

Förderung

  • Gachon University Gil Medical Center
  • National Research Foundation of Korea

Zitieren

APA

Park, S., Jeong, S., Kim, H. J., Lee, D. H., Choi, S. J., & Park, S. M. (2026). Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71261

Vancouver

Park S, Jeong S, Kim HJ, Lee DH, Choi SJ, Park SM. Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71261

BibTeX
@article{Park2026,
  author = {Park, Sangwoo and Jeong, Seogsong and Kim, Hye Jun and Lee, Dae Ho and Choi, Soo Jung and Park, Sang Min},
  title = {Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71261}
}
Kostenlos starten →